Aimmune, Regeneron teaming up for peanut allergy trial

Aimmune Therapeutics Inc. (NASDAQ:AIMT) said it will collaborate with Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Sanofi (Euronext:SAN; NYSE:SNY) to conduct a Phase II combination trial to treat peanut allergy. The trial, anticipated to begin next year, is to study Aimmune's AR101 in combination with dupilumab (REGN668, SAR231893) from Regeneron and Sanofi as adjunctive therapy.

Regeneron will sponsor the trial, and Aimmune will supply AR101 and food challenge materials. The partners will form a joint development committee. Aimmune said the collaboration includes no additional economic terms...